China NMPA Drug Inspection - Harbin Zhenbao Pharmaceutical Co., Ltd. - Ozagrel sodium for injection
China NMPA drug inspection for Harbin Zhenbao Pharmaceutical Co., Ltd. published October 29, 2020. Drug: Ozagrel sodium for injection. On October 29, 2020, the National Medical Products Administration (NMPA) released Announcement No. 73, identifying 18 ba
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Harbin Zhenbao Pharmaceutical Co., Ltd. published October 29, 2020. Drug: Ozagrel sodium for injection. On October 29, 2020, the National Medical Products Administration (NMPA) released Announcement No. 73, identifying 18 ba
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox